Marketing biologics is smaller, leaner, and more data-driven than traditional pharma. With the focus often on specialist physicians and on patient populations in the tens of thousands-or even thousands-direct and digital media are the primary outreach channels over advertising and print. In our experience with biologics, advertising is a low priority compared to the Web, medical meetings, and alternative media. Sometimes there's no advertising at all.
Marketing biologics is smaller, leaner, and more data-driven than traditional pharma. With the focus often on specialist physicians and on patient populations in the tens of thousands—or even thousands—direct and digital media are the primary outreach channels over advertising and print. In our experience with biologics, advertising is a low priority compared to the Web, medical meetings, and alternative media. Sometimes there's no advertising at all.
Biologics are expensive, so the ever-present challenges of access and patient adherence become magnified. Payers want hard data—not a form letter asserting medical need—before they pay for biologics, even for first-ever compounds. Patients need hands-on guidance in navigating insurance and other access options, as well as continual reinforcement to stay on a product that represents five- or six-figure revenue per Rx. A full-service agency for a biologic has to help create solutions to these issues, not just execute them.
If the biologic discovery company is comarketing the product, the client relationship can be very different. Bringing 12 people to an input meeting is a good way to alienate a biologic company partner. Bringing an intriguing idea—however rough, untested, or unasked for—is a good way to gain the respect and support of both partners.
Cambridge BioMarketing is a full-service healthcare marketing communications agency located in Cambridge, MA.
Telephone: 617-225-0001
E-mail: info@cambridgebmg.com
Web site: cambridgebmg.com
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.